查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023年至2028年早产及胎膜早破检验市场预测
市场调查报告书
商品编码
1410058

2023年至2028年早产及胎膜早破检验市场预测

Preterm Birth and Prom Testing Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

早产和胎膜早破检测市场预计将从 2021 年的 15.1 亿美元成长到 2028 年的 21.29 亿美元，复合年增长率为 5.03%。

早产和胎膜早破测试可以帮助辨识孕妇的胎膜破裂情况。识别破裂的胎膜使我们能够治疗患者并避免早产。由于生活方式障碍和压力等多种因素导致的早产和胎膜早破病例不断增加，是早产和胎膜早破检测市场的主要成长要素。此外，孕妇青少年怀孕和妊娠毒血症病例的增加也预计将对早产和胎膜早破检测市场产生正面影响。此外，政府倡议以及市场参与企业的产品发布和研究计划预计也将推动早产和胎膜早破测试市场的发展。

早产增加

由于不良生活习惯等多种因素导致的早产增加表明早产和胎膜早破检测市场的扩大。根据世界卫生组织统计，2020年报告了1,340万例早产（妊娠37週前出生），各国早产率介于4%至16%之间。此外，南亚和撒哈拉以南非洲地区的早产率最高，这些地区的早产儿死亡率也最高。全球65%以上的早产儿集中在这两个地区。

早产的负面影响

与早产和胎膜早破相关的众多併发症表明需要早期发现和预防早产，从而推动早产和胎膜早破检测市场的发展。例如，五岁以下儿童的主要死因是早产，2019年约有90万人死于早产。这可能是由呼吸系统不发达引起的呼吸问题、开放性动脉导管和低血压等心臟问题引起的。慢性健康问题，如坏死性小肠结肠炎、贫血、新生儿黄疸、低血糖、脑性麻痹、牙齿问题、感染疾病、气喘和饮食障碍，都是早产儿可能发生的长期併发症。这是一个例子影响。

青少年怀孕和妊娠毒血症呈上升趋势

早产与青春期妊娠、妊娠毒血症孕产妇健康问题密切相关。因此，青少年怀孕的增加和妊娠毒血症病例的增加预计将扩大早产和胎膜早破检测市场。据 NCBI 称，妊娠毒血症併发症每年导致 50,000 名孕产妇死亡和 50 万名胎儿死亡。青春期母亲（10至19岁）比女性（20至24岁）更容易患子痫、产后子宫内膜炎和全身性行为感染，并且更容易出现低出生体重、早产和严重疾病。其后代的新生儿疾病发病率更高。根据世界卫生组织预测，到2022年，全球10至14岁女性的青少年生育率为每1,000名女性生育1.5个孩子。

政府措施和研究计划

政府措施和研究计划正在推动胎膜早破测试的进步和采用，从而推动早产和胎膜早破测试市场的发展。例如，在低收入和中等收入国家，世卫组织进行研究以改善对孕妇和早产儿的照护。这些研究包括世卫组织行动试验（使用产前皮质类固醇改善早产儿结局）、婴儿早期生长摆动的营养管理试验以及扩大袋鼠母亲即时护理（KMC）规模的实施研究试验。此外，国际妇产科日誌(FIGO) 在 2021 年 10 月号的《国际妇产科杂誌》中推出了一个特别版块。本期特刊包括FIGO 关于有效管理和监测早产的九项良好实务建议。

北美地区预计将大幅成长

在预测期内，北美地区预计将占据早产和胎膜早破测试市场的主要份额。造成这一比例的因素包括早产率上升、技术进步以及意识的提高。例如，根据CDC资料，2021年的早产率比2020年增加了4%，为2007年以来最高，2021年美国出生的婴儿中大约有十分之一会遭受早产。 。

主要市场公司

Hologic Inc. 是一家总部位于美国的跨国公司，专注于女性健康领域。一种称为快速 fFN(R) 的周产期测试可评估孕妇早产的风险。该公司提供的其他早产和胎膜早破检测套组包括 QuikCheck fFN(R) 测试套件和 Rapid fFN(R) 10Q 盒式套件。 Sera Prognotics Inc. 是领先的女性健康公司之一，总部位于美国。 2023 年 2 月，该公司宣布了 Avert 早产试验关于降低新生儿发病率或死亡的积极顶线资料。这项研究是在威尔明顿的克里斯蒂娜护理中心进行的。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 调查过程

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
  • 产业价值链分析

第五章 早产和胎膜早破测试市场：按早产测试

  • 介绍
  • 骨盆腔检查
  • 超音波
  • 其他的

第六章 早产和舞会测试市场：按舞会测试

  • 介绍
  • 硝嗪试验
  • 蕨类植物测试
  • 其他的

第七章 早产和胎膜早破测试市场：依最终用户分类

  • 介绍
  • 诊断实验室
  • 医院
  • 其他的

第八章 早产和胎膜早破测试市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作

第十章 公司简介

  • Hologic, Inc
  • Abbott
  • Sera Prognostics Inc.
  • CooperSurgical Inc.
  • IQ Products
  • Qiagen NV
  • BHR Pharmaceuticals
  • NX Prenatal, Inc.
简介目录
Product Code: KSI061615710

The preterm birth and PROM testing market is expected to grow at a CAGR of 5.03% from US$1.510 billion in 2021 to US$2.129 billion in 2028.

Preterm birth and PROM testing aid in identifying fetal membrane rapture in pregnant women. The patient can be treated and a preterm birth can be avoided by identifying the ruptured fetal membrane. The rising cases of preterm birth and PROM due to several factors such as bad lifestyle, and stress are a major growth driver in the preterm birth and PROM testing market. Moreover, the increasing adolescent pregnancies and preeclampsia cases among pregnant women are further expected to positively impact the preterm birth and PROM testing market. Additionally, government efforts coupled with product launches and research projects by the market players are also contemplated to boost the preterm birth and PROM testing market.

Rising Cases of Preterm Birth

The increasing number of preterm births due to several factors such as bad lifestyle indicates the widening of the preterm birth and PROM testing market. In 2020, there were reportedly 13.4 million preterm births (births that occurred before 37 full weeks of pregnancy) according to the WHO, and Preterm birth rates in 2020 ranged from 4 to 16% across all nations. Moreover, preterm birth rates are highest in southern Asia and sub-Saharan Africa, and preterm infants in these areas have the highest mortality rates. More than 65% of preterm births worldwide are concentrated in these two areas. The study conducted by the Department of Obstetrics and Gynecology (University of Addis Ababa) in December 2022 revealed that the preterm PROM rate was 2.2% with a perinatal mortality rate of 206/1000.

Adverse Effects of Preterm Birth

There are numerous complications associated with preterm births and PROM which indicates the requirement of early detection and prevention of preterm births thereby propelling the preterm birth and PROM testing market. For instance, the primary factor in the death of children under the age of five is preterm birth problems, which accounted for almost 900,000 deaths in 2019. Breathing issues brought on by an underdeveloped respiratory system, heart issues including patent ductus arteriosus and low blood pressure, and other brief consequences are possible in people born preterm. Bleeding inside the head complications with the digestive system that can lead to necrotizing enterocolitis, anemia, and neonatal jaundice, hypoglycemia, cerebral palsy, learning disabilities, dental troubles, and chronic health conditions like infections, asthma, and feeding difficulties are examples of long-term repercussions that can affect the people born preterm.

Increasing Adolescent Pregnancy and Preeclampsia Cases

Preterm deliveries are closely associated with maternal health hazards, such as adolescent pregnancy and pre-eclampsia. The rising number of adolescent pregnancies and increasing preeclampsia cases are therefore contemplated to augment the preterm birth and PROM testing market. Preeclampsia complications cause 50,000 maternal deaths and 500,000 fetal deaths annually, according to NCBI. The chances of eclampsia, puerperal endometritis, and systemic infections are higher for adolescent mothers (10-19 years old) than for women (20-24 years old), and the risks of low birth weight, preterm birth, and severe neonatal conditions are higher for their offspring. According to the WHO, the anticipated global adolescent birth rate for females aged 10 to 14 in 2022 was 1.5 per 1000 women.

Government Efforts and Research Projects

The government efforts and research projects are encouraging the advancement and adoption of PROM testing thereby propelling the preterm birth and PROM testing market. For instance, in low- and middle-income nations, the WHO conducts research to improve care for pregnant women and preterm infants. These studies include the WHO ACTION Trials (Antenatal Corticosteroids for Improving Outcomes in Preterm Newborns), the Nutritional Management of Growth Flapping in Early Infancy Trial, and an implementation research trial to scale-up immediate kangaroo mother care (KMC). Moreover, the International Federation of Gynecology and Obstetrics (FIGO) launched a special section in the October 2021 issue of the International Journal of Gynecology and Obstetrics. This special section contains nine FIGO good practice recommendations for the effective management and monitoring of preterm birth.

North America is expected to grow Significantly

The North American region is expected to hold a significant share of the preterm birth and PROM testing market during the forecast period. Various factors attributed to such a share are the rising rate of preterm births, and technological advancements coupled with increased awareness. For instance, the preterm birth rate increased by 4% in 2021 as compared to 2020 which is the highest since 2007 as per the CDC data, and around one in 10 babies born in the US in 2021 suffered from preterm birth. Moreover, the presence of major market players such as Hologic, Abbott Laboratories, and Sera Prognostics Inc. is further expected to boost the preterm birth and PROM testing market in the region through enhanced accessibility.

Major Market Players

  • Hologic Inc. is a US-based multinational company focused on women's health. Perinatal testing called Rapid fFN® assesses a pregnant woman's risk of having a preterm birth. Other preterm and PROM kits offered by the company are the QuikCheck fFN® Test kit, Rapid fFN® 10Q Cassette Kit.
  • Sera Prognotics Inc. is one of the leading women's health companies headquartered in the US. In February 2023, the company announced the positive top-line data from Avert Preterm Trial in the reduction of neonatal morbidity or neonatal death. It was conducted at ChristianaCare in Wilmington.

Key Market Developments

  • In January 2023, to advance maternal health equity, the March of Dimes established a new preterm research centre at the University of Pennsylvania. It focuses on resolving the persistent racial inequities and poor health outcomes that make the United States the riskiest developed country for giving birth.
  • In August 2022, March of Dimes launched a new prematurity research hum at the University of California which focuses on using big data to gain insights into diagnostic and therapeutic tools to combat prematurity.

Segmentation:

By Preterm Birth Tests

  • Pelvic exam
  • Ultrasound
  • Others

By PROM Tests

  • Nitrazine Test
  • Ferning Test
  • Others

By End-User

  • Diagnostic Laboratories
  • Hospitals
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. PRETERM BIRTH AND PROM TESTING MARKET, BY PRETERM BIRTH TESTS

  • 5.1. Introduction
  • 5.2. Pelvic exam
  • 5.3. Ultrasound
  • 5.4. Others

6. PRETERM BIRTH AND PROM TESTING MARKET, BY PROM TESTS

  • 6.1. Introduction
  • 6.2. Nitrazine Test
  • 6.3. Ferning Test
  • 6.4. Others

7. PRETERM BIRTH AND PROM TESTING MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
  • 7.3. Hospitals
  • 7.4. Others

8. PRETERM BIRTH AND PROM TESTING MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

  • 10.1. Hologic, Inc
  • 10.2. Abbott
  • 10.3. Sera Prognostics Inc.
  • 10.4. CooperSurgical Inc.
  • 10.5. IQ Products
  • 10.6. Qiagen N.V.
  • 10.7. BHR Pharmaceuticals
  • 10.8. NX Prenatal, Inc.